NEKTAR THERAPEUTICS Item 2.05 Costs Associated with Exit or Disposal Activities.
On
In connection with these actions, Nektar expects to take an impairment charge of
Item 2.06 Material Impairments
Please see the disclosure relating to the estimated impairment charge in connection with the Reorganization Plans set forth under Item 2.05 "Costs Associated with Exit or Disposal Activities" of this Current Report on Form 8-K, which is incorporated by reference into this Item 2.06.
Cautionary Note Regarding Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements which can be
identified by words such as: "expect," "undertake," "will," "may," "estimate,"
"future," "seek," and similar references to future periods. Examples of
forward-looking statements include, among others, statements Nektar makes
regarding the future development plans for NKTR-358, NKTR-255 and other drug
candidates in research programs, Nektar's cost-reduction initiatives, and the
estimated impairment charges and costs that Nektar may incur in connection with
the reorganization and restructuring activities described above. Forward-looking
statements are neither historical facts nor assurances of future performance.
Instead, they are based only on Nektar's current beliefs, expectations and
assumptions regarding the future of its business, future plans and strategies,
anticipated events and trends, the economy and other future conditions. Because
forward-looking statements relate to the future, they are subject to inherent
uncertainties, risks and changes in circumstances that are difficult to predict
and many of which are outside of Nektar's control. Nektar's actual results may
differ materially from those indicated in the forward-looking statements.
Therefore, these forward-looking statements should not be relied upon. Important
factors that could cause actual results to differ materially from those
indicated in the forward-looking statements include, among others: (i) Nektar's
statements regarding the therapeutic potential of NKTR-358, NKTR-255 and other
drug candidates are subject to change as research and development continue to
generate new safety and efficacy data; (ii) NKTR-358, NKTR-255 and Nektar's
other drug candidates are investigational agents and continued research and
development for these drug candidates is subject to substantial risks, including
negative safety and efficacy findings in ongoing studies (notwithstanding
positive findings in earlier preclinical and clinical studies); (iii) NKTR-358,
NKTR-255 and Nektar's other drug candidates are in various stages of clinical
development and the risk of failure is high and can unexpectedly occur at any
stage prior to regulatory approval; (iv) the timing of the commencement or end
of clinical trials and the availability of clinical data may be delayed or
unsuccessful due to challenges caused by the COVID-19 pandemic, regulatory
delays, slower than anticipated patient enrollment, manufacturing challenges,
changing standards of care, evolving regulatory requirements, clinical trial
design, clinical outcomes and competitive factors; (v) Nektar may not achieve
the expected costs savings it expects from the restructuring and reorganization;
(vi) patents may not issue from Nektar's patent applications for its drug
candidates, patents that have issued may not be enforceable, or additional
intellectual property licenses from third parties may be required; and (vii)
certain other important risks and uncertainties set forth in Nektar's Annual
Report on Form 10-K filed with the
1© Edgar Online, source
